AstraZeneca PLC (AZN)vsSenti Biosciences Inc (SNTI)
AZN
AstraZeneca PLC
$185.95
-0.83%
HEALTHCARE · Cap: $282.69B
SNTI
Senti Biosciences Inc
$0.98
-0.86%
HEALTHCARE · Cap: $30.66M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 159049897% more annual revenue ($60.44B vs $38,000). AZN leads profitability with a 17.2% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
SNTI
Avoid14
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Intrinsic value data unavailable for SNTI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
No standout strengths identified
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : SNTI
SNTI has a balanced fundamental profile.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : SNTI
The primary concerns for SNTI are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 7.46 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while SNTI is a value play — different risk/reward profiles.
SNTI carries more volatility with a beta of 2.09 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 14/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Senti Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Senti Biosciences Inc (SNTI) is a cutting-edge biotechnology firm focused on advancing synthetic biology through its proprietary GeneCircuit platform, which enables the creation of programmable cell and gene therapies. The company is dedicated to addressing various diseases, including cancer and genetic disorders, with a strong emphasis on personalized medicine. Senti's promising development pipeline, combined with strategic partnerships, positions it well to lead the innovation of engineered cell therapies and provide transformative solutions to meet significant unmet medical needs within the biopharmaceutical landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?